Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers attribute this promising shift to the introduction of nearly a dozen new treatments for this form of skin cancer.
Tucatinib fights breast cancer that spreads to the brain
Last year, the FDA approved three new antibody-drug conjugates for treating cancer.
“In the era of targeted therapy, it is critical to know that a therapy is the right choice and is going to be effective.”
Researchers find a mechanism that enables lung cancer cells to lie dormant and avoid destruction by the cancer drugs.
A triple regimen of Opdivo, Yervoy and Cabometyx showed good antitumor activity, but severe side effects were common.
MK-6482 shrank tumors in 24% of people with advanced renal cell carcinoma.
TRK inhibitor larotrectinib led to durable responses in people with colon, pancreatic, appendix, bile duct and liver cancers.
Tecentriq plus Avastin improved both overall survival and patient-reported outcomes.
Clinical trials showed a high response rate, with almost 85% of participants experiencing tumor shrinkage with this targeted drug.
PARP inhibitor delays disease progression when used after successful chemotherapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.